Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235697 · ClinicalTrials.gov registry record · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
A Phase 3 study of Prostate Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT06235697: Recruiting Phase 3 study of Prostate Cancer, sponsored by Canadian Cancer Trials Group.
NCT06235697 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 710 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06235697, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Conditions Studied
Interventions
- RADIATION Radiation
- RADIATION Radiation SBRT only
- DRUG ADT
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente- Marshall Medical Offices - Redwood City
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Roseville - Roseville
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Kaiser Permanente Downtown Commons - Sacramento
- Kaiser Permanente-South Sacramento - Sacramento
- Kaiser Permanente-San Francisco - San Francisco
- Kaiser Permanente-Santa Teresa-San Jose - San Jose
- Kaiser Permanente San Leandro - San Leandro
- Kaiser San Rafael-Gallinas - San Rafael
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente-Santa Rosa - Santa Rosa
- Kaiser Permanente-South San Francisco - South San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2033-04-30 |
| Phase | Phase 3 |
What NCT06235697 shows while recruiting
NCT06235697 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radiation is the first listed.
NCT06235697 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT06235697 about?
NCT06235697 is a clinical study titled "Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment". This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation th...
What is the current status of trial NCT06235697?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2024-04-25. Estimated completion is 2033-04-30.
What conditions does trial NCT06235697 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06235697?
The interventions under investigation include: Radiation (RADIATION), Radiation SBRT only (RADIATION), ADT (DRUG).
Who is sponsoring clinical trial NCT06235697?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06235697 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06235697's enrollment target sits among peer trials
710 88th of 735 higher than 648 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI